A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer

A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer
Recruiting
99 years or below
All
Phase 2
7 participants needed
1 Location

Brief description of study

This study will test the experimental drug, ZEN003694, in combination with a marketed drug, talazoparib (Talzenna®), in patients with triple negative breast cancer (TNBC). Among the questions it will seek to answer are: 1. What are well-tolerated doses of ZEN003694 and talazoparib that can be given together without causing significant side effects? 2. What are the side effects of ZEN003694 when combined with talazoparib?

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: breast cancer
  • Age: 99 years or below
  • Gender: All


Updated on 19 Feb 2024. Study ID: 832893

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.